Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Report

Adjunctive treatment with infliximab in pediatric immunoglobulin A (IgA) vasculitis: A case report.

  • Authors : Castelli B; Rheumatology Unit, AOU Meyer Children's Hospital, Florence, Italy.; Marrani E

Subjects: IgA Vasculitis*/IgA Vasculitis*/IgA Vasculitis*/drug therapy ; Infliximab*/Infliximab*/Infliximab*/therapeutic use ; Tumor Necrosis Factor Inhibitors*/Tumor Necrosis Factor Inhibitors*/Tumor Necrosis Factor Inhibitors*/therapeutic use

  • Source: Pediatric dermatology [Pediatr Dermatol] 2022 Nov; Vol. 39 (6), pp. 946-949. Date of Electronic Publication: 2022 Jul 02.Publisher: Wiley Country of Publication: United States NLM ID: 8406799 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-1470

Record details

Read More Add to Saved list
×
Academic Journal

Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis.

  • Authors : Masui S; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.; Graduate School of Pharmaceutical Sciences, Kyoto University.

Subjects: Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Infliximab*/Infliximab*/Infliximab*/therapeutic use

  • Source: Biological & pharmaceutical bulletin [Biol Pharm Bull] 2023; Vol. 46 (8), pp. 1112-1119.Publisher: Pharmaceutical Society of Japan Country of Publication: Japan NLM ID: 9311984 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy ; Infliximab*/Infliximab*/Infliximab*/therapeutic use

  • Source: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Dec 05; Vol. 16 (12), pp. 1835-1844.Publisher: Oxford University Press Country of Publication: England NLM ID: 101318676 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease.

Subjects: Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/diagnosis ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy

  • Source: European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2022 Oct 01; Vol. 34 (10), pp. 1007-1014. Date of Electronic Publication: 2022 Jul 14.Publisher: Lippincott Williams And Wilkins Country of Publication: England NLM ID: 9000874 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.

  • Authors : Kantasiripitak W; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.; Outtier A

Subjects: Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy ; Infliximab*/Infliximab*/Infliximab*/pharmacokinetics ; Infliximab*/Infliximab*/Infliximab*/therapeutic use

  • Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Aug; Vol. 11 (8), pp. 1045-1059. Date of Electronic Publication: 2022 Jun 15.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.

  • Authors : Brun MK; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Subjects: Antibodies* ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/adverse effects ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy

  • Source: Journal of internal medicine [J Intern Med] 2022 Sep; Vol. 292 (3), pp. 477-491. Date of Electronic Publication: 2022 Apr 26.Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 8904841 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Neurotuberculosis with paradoxical reaction treated with infliximab: case report and literature review.

  • Authors : Chia G; Internal Medicine Wellington Regional Hospital, New Zealand.; Bartlett T

Subjects: Infliximab*/Infliximab*/Infliximab*/therapeutic use ; Tuberculosis, Central Nervous System*/Tuberculosis, Central Nervous System*/Tuberculosis, Central Nervous System*/drug therapy; Female

  • Source: The New Zealand medical journal [N Z Med J] 2022 Aug 05; Vol. 135 (1559), pp. 118-121. Date of Electronic Publication: 2022 Aug 05.Publisher: Pasifika Medical Association Group Country of Publication: New Zealand NLM ID: 0401067 Publication Model: Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Report

Clinical Decision Support Tool for Infliximab in Crohn's Disease.

  • Authors : Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, California. Electronic address: .; Wong ECL

Subjects: Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy ; Decision Support Systems, Clinical* ; Infliximab*/Infliximab*/Infliximab*/therapeutic use

  • Source: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2022 May; Vol. 20 (5), pp. Publisher: W.B. Saunders for the American Gastroenterological Association Country of Publication: United States NLM ID: 101160775 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab.

Subjects: Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy ; Infliximab*/Infliximab*/Infliximab*/administration & dosage; Antibodies

  • Source: European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2022 Mar 01; Vol. 34 (3), pp. 295-301.Publisher: Lippincott Williams And Wilkins Country of Publication: England NLM ID: 9000874 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases-Reply.

  • Authors : Syversen SW; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Jahnsen J

Subjects: Drug Monitoring* ; Gastrointestinal Agents*/Gastrointestinal Agents*/Gastrointestinal Agents*/analysis ; Gastrointestinal Agents*/Gastrointestinal Agents*/Gastrointestinal Agents*/therapeutic use

  • Source: JAMA [JAMA] 2022 Apr 19; Vol. 327 (15), pp. 1506-1507.Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×